Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

Patient Case Work-Up

Guidelines for Molecular Testing

Considerations for Molecular Testing

Patient Case Test Results

Importance of Waiting for Molecular Test Results

PD-L1 Treatment vs Targeted Therapy

First-Line Treatment Selection

CNS Penetration

Considerations for Sequencing Osimertinib

Improving Outcomes With First- and Second-Generation EGFR TKIs

Patient Case Hypotheticals

Patient Case Disease Progression

Mechanisms of Resistance to Osimertinib Data From Second-Line Treatment

Mechanisms of Resistance to Osimertinib Preliminary Data From First-Line Treatment

Liquid vs Tissue Biopsy

Patient Case Disease Progression

Chemoimmunotherapy

Concluding Remarks

Abbreviations